EGFR and non-small cell lung carcinoma: Two recent clinical trials, LUX-Lung 744 and ARCHER-1050,45 have demonstrated that second-generation EGFR-TKIs significantly prolong progression-free survival in patients with EGFR-mutant NSCLC compared to first-generation inhibitors.